It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look ...

Just seven weeks after projecting an 18% revenue boost for this year, Indivior has slashed its estimate to an 8% increase, ...

The two companies’ applications for China-approved PD-1 inhibitor camrelizumab and the VEGFR tyrosine kinase inhibitor ...

Editor's note: This story was corrected to note that Brooks will be Eli Lilly's interim CFO. A little more than a month after ...

Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma ...

While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and ...

Roche has claimed the top spot in a ranking of the online presence of drugmakers, climbing two spots on the strength of its ...

A storm of scrutiny relating to Johnson & Johnson’s pricing and patenting of its tuberculosis med bedaquiline (branded as ...

Johnson & Johnson will pay Emergent BioSolutions $50 million to settle a two-year contract squabble and bring closure to an ...

Novo Nordisk’s massively successful GLP-1 analog semaglutide, the active ingredient in the popular diabetes and obesity meds ...

Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? | Is Eli Lilly’s Mounjaro ...

Ahead of an election in November—and amid a period of legislative uncertainty for the China-targeting BIOSECURE Act—U.S.